Menlo Park, CA 10/31/18—Akoya Biosciences, a provider of solutions for tissue phenotyping, has acquired PerkinElmer’s Phenoptics portfolio, consisting of the Mantra, Vectra and Vectra Polaris multiplex immunofluorescence systems. Akoya provides the CODEX tissue analysis system. “With both the Phenoptics portfolio and CODEX, Akoya will provide our customers with a full suite of end-to-end solutions for high-parameter tissue analysis,” commented Akoya CEO Brian McKelligon.“ Akoya Bioscience’s CODEX systems are designed for multiparameter tissue analysis. Terry Lo, general manager of the Phenoptics team, will serve as president of Akoya.

PerkinElmer stated in its third quarter earnings call that the sale price was $37 million and that the business had nine month revenues of $23 million. The divestment is not expected to impact 2018 adjusted EPS. Both the acquired and legacy Akoya Biosciences products address the pathology research market, providing multiplexed alternatives to traditional immunohistochemistry. PerkinElmer launched the Mantra system in 2014, the first of the three divested systems, as part of a workflow that also included assays, reagents, software and contract research services.